BRISBANE, AUSTRALIA, 29 JUL 2021 – MGI, a world-leading life science technology innovator, announces the opening of MGI Australia Demonstration Laboratory (Demo Lab) to support the users in Asia-Pacific (APAC). The lab is dedicated to offering the APAC researchers and users unique access to MGI's cutting-edge technology portfolio including DNBSEQ platforms*, laboratory automation systems and bioinformatics products, for application development, technology assessment and technical support. MGI Australia will announce a $100,000-worth grant program to APAC scientists in August.
The Demo Lab acts as a centralized customer support center to provide troubleshooting, technology trials, validation or proof-of-concept programs, and other technical support for MGI platform users in the region. Locally incorporated in February, MGI Australia is committed to the vision of leading life science innovation and providing innovative technology and products for scientists and health professionals in ANZ. Dr. Bicheng Yang, Director of MGI Australia, introduces that “the Demo Lab also serves as a Research and Development center to conduct innovative application developments with regional focus and importance.”
The Demo Lab showcases a suite of MGI's proprietary technology platforms covering the whole genome-sequencing process including a series of ultra-high, high and medium throughput DNBSEQ sequencers*, automated laboratory systems, and bioinformatics products, with the goal to sharpen existing technical strengths and grow local capabilities to support the users in accelerating their research and applications. MGI genetic sequencers*, based on the proprietary sequencing technology DNBSEQ™ feature low amplification error rate, high density patterned arrays, high SNP and indel detection accuracy, and low index hopping. The Demo Lab is equipped with MGI's most powerful sequencer to date DNBSEQ-T7*, a highly flexible production-scale platform that can produce as many as 60 whole human genomes in one day and drive down the sequencing cost significantly. DNBSEQ-G400* High-Throughput Sequencer and DNBSEQ-G50* Medium-Throughput Sequencer accommodate different applications, throughput needs and budgets.
MGI automated laboratory systems simplify the labour-intensive and time-consuming procedures in a sequencing laboratory such as sample preparation, DNA/RNA extraction, and liquid transfer, and enable a highly efficient streamlined workflow. MGI's flagship automation products including MGISP-960 High-throughput Automated Sample Preparation System, MGISP-NE32 Automated Nucleic Acid Extractor, and MGISTP-3000 Benchtop Automated Sample Transfer System are also housed in the Demo Lab. MGI automation systems are playing an instrumental role in the global pandemic control including Australia by enabling fast-turn-around COVID-19 testing.
MGI Australia has a strong local technical team of operations managers, field application scientists, and engineers offering on-the-ground support for local customers. The well-functioning local team has implemented over 70 innovative systems to date proudly supporting ANZ customers. MGI Australia will announce a $100,000-worth grant program in August that will be open to all researchers from the Asia-Pacific region. Email us here to join our mail list to receive grant updates.
Since the establishment in 2016, MGI has independently developed a full range of patented technologies, including sequencing*, patterned array, fluidics, opto-electromechanics and more. MGI has more than 140 valid Patent Cooperation Treaty (PCT) patents applications filed globally. The MGI platform is gaining wide industry recognition in the scientific community around the world, with over 1,600 papers using DNBSEQ™ sequencing* platform published in top scientific journals and over 40 petabytes of data generated to date. Committed to continuous heavy investment in Research and Development, MGI is highly driven to advance the status quo of the global genome sequencing industry by empowering the customers with competitive advantages of innovation, quality and affordability.
MGI (MGI Tech Co., Ltd.), headquartered in Shenzhen, is committed to building core tools and technology to lead life science through intelligent innovation. Based on its proprietary technology, MGI focuses on Research & Development, production and sales of sequencing instruments, reagents, and related products to support life science research, agriculture, precision medicine and healthcare. MGI is a leading producer of clinical high-throughput gene sequencers, and its multi-omics platforms include genetic sequencing*, medical imaging, and laboratory automation. MGI’s mission is to develop and promote advanced life science tools for future healthcare. For more information please visit MGI website or connect us on Twitter, Linkedinor Youtube.
*Unless otherwise informed, all sequencers and sequencing reagents are not available in Germany, USA, Spain, UK, Hong Kong, Sweden, and Belgium.